Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 6 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

Spending time indoors during childhood ups risk of developing multiple sclerosis

13 Jan 2019

Low levels of sun exposure throughout childhood appears to be associated with an increased risk of developing multiple sclerosis (MS) in adulthood, a study reports. Notably, the risk is greatest in those who spend most time indoors and use sun protection frequently in their limited time outdoors.

The study included 2,251 MS patients and 4,028 non-MS controls enrolled in the Environmental Risk Factors in MS (EnvIMS) study. The participants provided data on their sun exposure behaviours for 5-year age intervals from birth, with the study focusing on the first three age intervals (≤15 years).

Researchers compared two conceptual life course epidemiology models that can be used to explain disease aetiology: the critical period and accumulation models. The critical period model suggests the existence of a time period during which an individual is susceptible to exposures that determine disease risk, whereas the accumulation model suggests that longer duration of exposure time heightens the risk of disease in individuals irrespective of when exposure occurs.

Based on the results, the accumulation model emerged as the best model, which demonstrated that the lowest vs highest sun exposure at all three age intervals yielded a nearly 50-percent increased risk of MS (risk ratio [RR], 1.47; 95 percent CI, 1.24–1.74).

On latent class analysis, the highest risk of MS was observed in the group of individuals with low sun exposure during both summer and winter and high sun protection use than in the group with high sun exposure and low sun protection use (RR, 1.76; 1.27–2.46).

The findings underscore the importance of promoting balanced safe sun exposure practices tailored to specific populations in order to reduce disease burden, especially in countries and cultures where children spend a lot of time indoors, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 6 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.